Pharmacyclics to Present at Bank of America Merrill Lynch Healthcare Conference and MDB Bright Lights Conference
SUNNYVALE, Calif., May 6 Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune mediated diseases and cancer, today announced presentations at two investor conferences in the coming week. David Loury PhD, Chief Scientific Officer, will be presenting at the MDB Bright Lights Conference in San Francisco, CA at the Palace Hotel on Tuesday, May 11 at 4:00 P.M. PDT. Joseph Buggy PhD, Vice President of Research, will be presenting at the Bank of America Merrill Lynch Healthcare Conference in New York, NY at the Grand Hyatt on Wednesday, May 12 at 4:20 P.M. EDT/1:20 P.M. PDT.
There will be a live webcast of the Bank of America Merrill Lynch conference presentation, which will be accessible through a link posted on the investor relations/events & webcasts section of the PCYC website, please go to http://ir.pharmacyclics.com/events.cfm
Pharmacyclics(R) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of immune mediated disease and cancer. Our mission and goal are worth repeating: to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs. To identify promising product candidates based on exceptional scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate. We exist to make a difference for the better and these are important times to do just that.
The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.
SOURCE Pharmacyclics, Inc.
You May Also Like